D.E. Shaw & Co
TBPH icon

D.E. Shaw & Co’s Theravance Biopharma TBPH Stock Holding History

D.E. Shaw & Co’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-40,000
Closed -$924K – 4249
2020
Q1 		$924K Hold
40,000
– – ﹤0.01% 2794
2019
Q4 		$1.04M Sell
40,000
-500
-1% -$9.72K ﹤0.01% 2961
2019
Q3 		$789K Hold
40,500
– – ﹤0.01% 2956
2019
Q2 		$661K Buy
+40,500
New +$821K ﹤0.01% 2924

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's TBPH Position: Q2 2026 in Review

D.E. Shaw & Co increased its Theravance Biopharma (TBPH) stake by 24% in Q2 2026, buying an estimated $3.83M and bringing the position to 1,185,390 shares worth $20.2M. The position accounts for 0.01% of the portfolio, ranked #1279.

D.E. Shaw & Co first reported a position in TBPH in Q2 2014 and has held it in 46 quarters since. The position peaked at $23.6M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • D.E. Shaw & Co held 1,185,390 shares of Theravance Biopharma worth $20.2M as of Q2 2026.
  • D.E. Shaw & Co bought 231,348 Theravance Biopharma shares in Q2 2026, an estimated $3.83M.
  • Theravance Biopharma made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1279 holding.
  • D.E. Shaw & Co first reported a position in Theravance Biopharma in Q2 2014 and has held it in 46 quarters since.
  • D.E. Shaw & Co's Theravance Biopharma position peaked at $23.6M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.